Krystal Biotech (KRYS) Stock Price, News & Analysis

Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Key Stats

• Today's Range: $127.99 to $132.35
• 50-Day Range: $123.36 to $170.57
• 52-Week Range: $122.80 to $219.34
• Volume: 352,500 shs
• Average Volume: 303,196 shs
• Market Capitalization: $3.82 billion
• P/E Ratio: 31.75
• Dividend Yield: N/A
• Price Target: $211.13
• Consensus Rating: Buy

Krystal Biotech Stock Analysis - MarketRank™

Krystal Biotech scored higher than 90% of companies evaluated by MarketBeat, and ranked 103rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Krystal Biotech has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 64.17%

Earnings Growth

Earnings for Krystal Biotech are expected to grow by 64.17% in the coming year, from $6.14 to $10.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Krystal Biotech is 31.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Krystal Biotech is 31.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.28.

Price to Book Value per Share Ratio

Krystal Biotech has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.82% of the float of Krystal Biotech has been sold short.

Short Interest Ratio / Days to Cover

Krystal Biotech has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Krystal Biotech has recently increased by 12.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Krystal Biotech does not currently pay a dividend.

Dividend Growth

Krystal Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.87

Percentage of Shares Shorted

11.82% of the float of Krystal Biotech has been sold short.

Short Interest Ratio / Days to Cover

Krystal Biotech has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Krystal Biotech has recently increased by 12.31%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.87

News Sentiment

Krystal Biotech has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Krystal Biotech this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Krystal Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.70% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KRYS Stock Analysis - Frequently Asked Questions

How have KRYS shares performed this year?

Krystal Biotech's stock was trading at $156.66 at the start of the year. Since then, KRYS stock has decreased by 15.7% and is now trading at $132.09.
View the best growth stocks for 2025 here.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings data on Tuesday, May, 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by $0.18. The firm earned $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a trailing twelve-month return on equity of 14.64% and a net margin of 37.17%.
Read the conference call transcript.

When did Krystal Biotech IPO?

Krystal Biotech (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

Who are Krystal Biotech's major shareholders?

Top institutional investors of Krystal Biotech include Vanguard Group Inc. (9.78%), Redmile Group LLC (2.55%), Frazier Life Sciences Management L.P. (2.38%) and UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (1.99%). Insiders that own company stock include Krish S Krishnan, Suma Krishnan, Daniel Janney, Dino A Rossi, Kathryn Romano, Andrew C Orth and Julian S Gangolli.
View institutional ownership trends.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/19/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRYS
• CIK: 1711279
• Web: www.krystalbio.com
• Phone: (412) 586-5830
• Fax: N/A
• Employees: 210
• Year Founded: 2017

Price Target and Rating

• Average Stock Price Target: $211.13
• High Stock Price Target: $245.00
• Low Stock Price Target: $155.00
• Potential Upside/Downside: +59.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $4.16
• Trailing P/E Ratio: 31.75
• Forward P/E Ratio: 21.51
• P/E Growth: N/A
• Net Income: $89.16 million
• Net Margins: 37.17%
• Pretax Margin: 41.39%
• Return on Equity: 14.64%
• Return on Assets: 13.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.65
• Quick Ratio: 9.27

Sales & Book Value

• Annual Sales: $290.52 million
• Price / Sales: 13.14
• Cash Flow: $4.71 per share
• Price / Cash Flow: 28.04
• Book Value: $32.90 per share
• Price / Book: 4.01

Miscellaneous

• Outstanding Shares: 28,900,000
• Free Float: 24,940,000
• Market Cap: $3.82 billion
• Optionable: Optionable
• Beta: 0.65